Quick Answer
ProMIS Neurosciences Inc. reported Net Income of -$39.72 million for fiscal year 2025.
ProMIS Neurosciences Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$39.72M -1529.3% |
$2.78M +121.0% |
-$13.21M +26.9% |
-$18.06M -84.5% |
-$9.79M | — |
| Diluted EPS | -$22.61 -959.7% |
$2.63 +345.8% |
-$1.07 +55.6% |
-$2.41 -42.6% |
-$1.69 | — |
| Total Assets | $9.18M -51.4% |
$18.91M +38.9% |
$13.62M +96.7% |
$6.92M -61.0% |
$17.75M | — |
| Cash and Equivalents | $6.12M -54.0% |
$13.29M +5.5% |
$12.60M +114.4% |
$5.88M -65.3% |
$16.94M | — |
| Long-Term Debt | — | — | — | — | $3.91M | — |
| Stockholders Equity | -$1.26M -107.6% |
$16.49M +339.3% |
$3.75M +378.5% |
-$1.35M -123.8% |
$5.66M +810.5% |
-$796.7K |
| R&D Expense | $33.38M +213.8% |
$10.64M +34.9% |
$7.88M -51.0% |
$16.09M +247.7% |
$4.63M | — |
| Operating Income | -$40.17M -138.7% |
-$16.83M -18.0% |
-$14.26M +39.0% |
-$23.38M -182.0% |
-$8.29M | — |
| Shares Outstanding | 2.15M +64.6% |
1.31M -93.1% |
18.89M +120.1% |
8.58M +19.2% |
7.20M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$11.58M | -224.8% | -14.5% |
| Diluted EPS | September 30, 2025 | -$0.24 | -177.4% | +17.2% |
| Total Assets | September 30, 2025 | $21.46M | -12.5% | +125.6% |
| Cash and Equivalents | September 30, 2025 | $15.40M | -28.5% | +241.4% |
| Long-Term Debt | December 31, 2021 | $3.91M | — | — |
| Stockholders Equity | September 30, 2025 | $9.19M | +26.3% | +2501.4% |
| R&D Expense | September 30, 2025 | $9.80M | +282.1% | +12.0% |
| Operating Income | September 30, 2025 | -$11.75M | -165.0% | -15.4% |
| Shares Outstanding | September 30, 2025 | 53.81M | +64.6% | +64.6% |
- ProMIS Neurosciences Inc. reported Net Income of -$39.72 million for fiscal year 2025.
- ProMIS Neurosciences Inc. showed a decrease of -1529.3% in Net Income compared to the prior fiscal year.
- ProMIS Neurosciences Inc. reported Diluted EPS of $22.61 per share (loss) for fiscal year 2025.
- ProMIS Neurosciences Inc. showed a decrease of -959.7% in Diluted EPS compared to the prior fiscal year.
- ProMIS Neurosciences Inc. reported Total Assets of $9.18 million for fiscal year 2025.
- ProMIS Neurosciences Inc. showed a decrease of -51.4% in Total Assets compared to the prior fiscal year.
- ProMIS Neurosciences Inc. reported Cash and Equivalents of $6.12 million for fiscal year 2025.
- ProMIS Neurosciences Inc. showed a decrease of -54.0% in Cash and Equivalents compared to the prior fiscal year.
- ProMIS Neurosciences Inc. reported Long-Term Debt of $3.91 million for fiscal year 2021.
- ProMIS Neurosciences Inc. reported Stockholders Equity of -$1.26 million for fiscal year 2025.
- ProMIS Neurosciences Inc. showed a decrease of -107.6% in Stockholders Equity compared to the prior fiscal year.
- ProMIS Neurosciences Inc. reported R&D Expense of $33.38 million for fiscal year 2025.
- ProMIS Neurosciences Inc. showed an increase of +213.8% in R&D Expense compared to the prior fiscal year.
- ProMIS Neurosciences Inc. reported Operating Income of -$40.17 million for fiscal year 2025.
- ProMIS Neurosciences Inc. showed a decrease of -138.7% in Operating Income compared to the prior fiscal year.
- ProMIS Neurosciences Inc. reported Shares Outstanding of 2.15 million shares for fiscal year 2025.
- ProMIS Neurosciences Inc. showed an increase of +64.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: